Emloyment Law Group - Law Firms - Whistleblower Lawyers
Live Chat Contact Us 24/7 Email US
Contact Us: Live Chat, Call, Email Chat email

Use of this form does not establish an attorney-client relationship. As a next
step, you will hear from a client specialist.

Our Clients in Their
Own Words
Play Video: Whistleblower Attorney Testimonials | Wendell Carter
Previous Video
Next Video

Toll Free: 1-888-826-5260
Fax: 202-261-2835

[email protected]

1717 K St. NW
Ste 1110
Washington, DC 20006-5345

The Employment Law Group,PC. BBB Business Review

Whistleblower Law Blog

Healthpoint Ltd. and DFB Pharmaceuticals Agree to Pay $48 Million False Claims Act Settlement for Submitting Claims for Unapproved Prescription Drug

Healthpoint Limited and DFB Pharmaceuticals have agreed to pay the federal government up to $48 million to settle allegations that they submitted false claims for an unapproved drug ineligible for reimbursement through Medicare and Medicaid. Under the settlement agreement, Healthpoint and DFB will pay $28 million, plus an additional $20 million if in the next three years there is a change in ownership of Healthpoint or DFB.

The medicaid fraud lawsuit claims that Healthpoint launched Xenaderm, a prescription drug for treating bedsores on patients in nursing homes, without ever receiving Food and Drug Administration (FDA) approval. Under the Federal Food Drug and Cosmetic Act, drug manufacturers must first receive FDA approval before they are able to introduce any new drugs to the market and before they can request Medicare and Medicaid reimbursement.

The Department of Justice alleges that Healthpoint intended to market Xenaderm as a new prescription ointment modeled after drugs that were on the market before October 1962.  In doing this, Healthpoint was attempting to avoid the time, effort, and expense associated with receiving FDA approval. Furthermore, Healthpoint allegedly misrepresented the regulatory status of Xenaderm in its quarterly reports submitted to the government.  In fact, Healthpoint failed to complete a double-blind placebo-controlled clinical study, which never established the effectiveness or safety of Xenaderm.

“This resolution is yet another example of the government’s enduring efforts to ensure that drug manufacturers comply with the critical FDA requirements for the efficacy of their drugs and the integrity of their data,” said U.S. Attorney Carmen M. Ortiz.   “This office will continue to vigorously police these key requirements that ensure that the public has access to, and the government pays only for effective medications.”

The Employment Law Group® law firm’s whistleblower attorneys have helped many clients file suit against employers that fraudulently bill the U.S. government, and have established favorable precedents under the retaliation provision of the False Claims Act.

Tagged: ,

decorative line
facebook logo twitter logo linkedin logo
Home  |  What We Do  |  Our Team  |  Our Clients  |  In The News  |  Resources  |  Contact Us

Our Location: Washington, D.C.

© 2021 The Employment Law Group, P.C. - All rights reserved.
Disclaimer | Terms of Use | Privacy Policy